Cinnamtannin B-1 Inhibits the Progression of Osteosarcoma by Regulating the miR-1281/PPIF Axis

Area of Science:

• Oncology
• Molecular Biology
• Natural Products Chemistry

Background:

• Osteosarcoma (OS) is a primary bone cancer affecting children and adolescents, with a 5% incidence rate.
• Cinnamtannin B-1 (CTB-1), a trimeric proanthocyanidin from Cinnamomum zeylanicum and Laurus nobilis, has shown effects on other cancers but its role in OS is unknown.
• MicroRNAs (miRNAs) are increasingly recognized for their involvement in tumor proliferation.

Purpose of the Study:

• To investigate the effects of CTB-1 on osteosarcoma (OS) cell proliferation and identify underlying molecular mechanisms.
• To explore the role of specific microRNAs (miRNAs) in CTB-1-mediated inhibition of OS.
• To elucidate the signaling pathway involved in CTB-1's anti-cancer activity in OS.

Main Methods:

• Osteosarcoma (OS) cell lines (HOS and MG-63) were treated with varying doses of Cinnamtannin B-1 (CTB-1).
• MicroRNA (miRNA) sequencing was performed on HOS cells post-CTB-1 treatment to identify differentially expressed miRNAs.
• Functional assays, including cell growth, migration, and invasion assays, were conducted, along with rescue experiments to validate the miR-1281/PPIF pathway.

Main Results:

• CTB-1 inhibited OS cell proliferation in a dose-dependent manner, correlating with increased cell survival rates.
• MiRNA sequencing revealed significant upregulation of miR-1281 expression in CTB-1-treated HOS cells.
• CTB-1 inhibited OS cell growth and migration by upregulating miR-1281, which in turn suppressed Peptidylprolyl Isomerase F (PPIF) expression via a sponging mechanism.

Conclusions:

• CTB-1 effectively inhibits osteosarcoma (OS) cell growth, invasion, and migration.
• The anti-cancer effects of CTB-1 in OS are mediated through the upregulation of miR-1281 and subsequent inhibition of PPIF.
• CTB-1 represents a promising therapeutic candidate for osteosarcoma treatment, targeting the miR-1281/PPIF pathway.